New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTSI, SI, SI, THOR, THOR, THOR, STJ, STJ, STJ, ATRC, ATRC, ATRC, CADX, CADX, CADX, COV, COV, COV, CRY, CRY, CRY, EW, EW, EW, HTWR, HTWR, HTWR, ISRG, ISRG, ISRG, MDT, MDT, MDT, MYGN, MYGN, MYGN, RTIX, RTIX, RTIX, WTKWY, WTKWY, WTKWYAmerican Association for Thoracic Surgery to hold annual meeting
94th Annual Meeting of AATS is being held in Toronto on April 26-30.
News For SI;RTIX;MYGN;MDT;ISRG;HTWR;EW;CRY;COV;CADX;ATRC;STJ;THOR;WTKWY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
08:45 EDTISRGIntuitive Surgical price target raised to $600 from $550 at BofA/Merrill
Subscribe for More Information
December 19, 2014
12:12 EDTMYGNMyriad Genetics receives FDA approval of BRACAnalysis CDx
Myriad Genetics (MYGN) announced that it has received approval from the U.S. FDA for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's (AZN) drug Lynparza. Lynparza is the first poly ADP-ribose polymerase inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy. BRACAnalysis CDx is Myriad's first FDA-approved companion diagnostic for use with a novel PARP inhibitor. BRACAnalysis CDx is a highly accurate molecular companion diagnostic test that identifies deleterious or suspected deleterious mutations in the BRCA1 and BRCA2 genes, using DNA obtained from a blood sample. BRACAnalysis CDx was proven in clinical studies to effectively identify patients with BRCA mutations who would be candidates for Lynparza. The approval of BRACAnalysis CDx demonstrates Myriad's commitment to developing companion diagnostics and is the culmination of an intensive, multiyear scientific collaboration with AstraZeneca to advance personalized medicine for women with ovarian cancer.
10:17 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTMYGNMyriad Genetics initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 17, 2014
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information
05:23 EDTSTJSt. Jude Medical announces CE Mark approval of Quadra Allure MP CRT-P
Subscribe for More Information
December 9, 2014
08:44 EDTWTKWYWolters Kluwer to host investor day with a conference call hookup
Subscribe for More Information
08:07 EDTEWEdwards Lifesciences price target raised to $155 from $135 at JMP Securities
Subscribe for More Information
07:36 EDTEWEdwards Lifesciences TAVI growth reinforces bullish stance, says Canaccord
Subscribe for More Information
07:07 EDTEWEdwards price target raised to $151-$152 from $135-$140 at Wells Fargo
Wells Fargo increased its price target on Edwards Lifesciences as the firm believes that the company's roughly in-line 2015 guidance announced yesterday is conservative.The firm also notes that the company raised its long-term TAVR market assumption to over $3B in 2019. The firm keeps an Outperform rating on the shares.
December 8, 2014
08:16 EDTEWEdwards Lifesciences announces investments in CardioKinetix
Edwards made a structured investment in CardioKinetix, a privately held medical device company pioneering a catheter-based treatment for heart failure. This transaction increases Edwards' existing minority interest in CardioKinetix and provides an option to purchase the remaining outstanding shares for a future payment, plus additional milestone payments based on future regulatory and reimbursement approvals. In the second investment, the company acquired intellectual property that broadens its transcatheter mitral valve development efforts. Additional details of both investments were not disclosed.
08:15 EDTEWEdwards Lifesciences sees FY15 EPS $3.90-$4.10, consensus $3.96
Subscribe for More Information
08:12 EDTEWEdwards Lifesciences backs FY14 EPS $3.33-$3.39, consensus $3.39
Subscribe for More Information
06:05 EDTEWEdwards Lifesciences to host investor meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use